Error message

Enter key-codes to unlock Personalized Downloads field is required.

"Thanks to new Multiplicom test kits physicians are able to identify all the genetic mutations of a condition at once, and use this information to initiate the right - personalized - treatment.”

Our DNA

We believe that molecular diagnostic kits are essential to providing everyone with access to effective, affordable and personalized medicine.

read more

OUR WHY

By detecting a genetic predisposition to certain illnesses at an early stage we make personalized medicine possible. That allows us to contribute to improved quality of life and to a healthier society.

OUR HOW

We take the information that is stored in the DNA of each individual to provide correct and reliable information about the origin of certain illnesses, or to better understand a potential predisposition to these illnesses. That allows the physician to intervene more quickly and efficiently through personalized medicine. Early diagnosis and targeted treatment results in improved health of the individual without increasing the healthcare costs for society! This way we opt for an affordable and accessible approach.

OUR WHAT

We develop simple, efficient and reliable molecular diagnostic test kits to collect genetic information for personalized treatment.

close


Our Values

Everything starts with our continuous search for INNOVATIVE test kits in molecular diagnostics. Our objective is to translate complexity into practical solutions. Using our expertise, we aim to provide clinical laboratories user-friendly applications. Quickly and correctly. TRUSTWORTHY for all stakeholders.

read more

There is only an added value to collecting genetic information early if the individual BENEFITS from it. Early prevention or the appropriate medical approach. Because everyone should be entitled to personalized medicine. APPROACHABLE for all. We therefore continue to invest in various domains: human genetics, onco genetics and prenatal genetics.

We do this with an open mind and a healthy INTERNATIONAL ambition. Because we believe that personalized medicine must not only open frontiers, it must cross those frontiers as well.

close


Our History

Founded in 2011 as a spin-off from the University of Antwerp and VIB, Multiplicom achieved end of 2012 its first CE-IVD-certification for the BRCA MASTR Dx assay for breast and ovarian cancer predisposition. It was the first company in Europe achieving a BRCA CE-IVD certification and it continues to develop and market quality controlled MPS-based assays.

read more

Therefore, it enables clinical laboratories to diagnose patients with a genetic disease or predisposition, steer cancer therapy, and identify congenital defects early in pregnancy. 

close


Quality Standards

Our MASTR technology has been developed and proven to obtain a high level of reliability. We aim to register our major products under the CE-IVD directives and maintain an ISO13485 quality standard.

read more

CE-IVD

 

CE marked Products

Multiplicom has heavily invested in setting up a quality system that meets the European CE-IVD requirements.  As a result, the company has been able to design, develop and manufacture CE-IVD products that are conform to the Essential requirements outlined in Annex I of the IVD Directive. Multiplicom's CE-IVD products that are placed on the market are therefore safe, effective and suitable for their purpose.

  • BRCA MASTR Dx (2012) for Breast and Ovarian Cancer
  • CFTR MASTR Dx (2014) for Cystic Fibrosis
  • FMF MASTR Dx (2014) for Familial Mediterranean Fever
  • Clarigo (2015) screens for the aneuploidy status of chromosomes 21, 18 and 13 early in pregnancy
  • BRCA Tumor MASTR Plus Dx (2016) for the identification of mutations in BRCA1 and BRCA2 in FFPE tumor samples
  • SOMATIC 1 MASTR Plus Dx (2016) for the identification of mutations in NRAS, KRAS and BRAF genes in cancer patients

 

 

Benefits of Multiplicom's Dx, CE-IVD products

  • Offers greater confidence on results obtained
  • Guarantees that reagents have been designed and manufactured in such way that do not compromise, directly or indirectly, the clinical condition or the safety of the patients and the safety or health of those utilizing the kit during the testing
  • Facilitates the accreditation process of a medical laboratory performing clinical testing services while reducing evaluation costs

Download CE-IVD BRCA MASTR Dx - CFTR MASTR Dx - FMF MASTR Dx - 454 MID Dx - MID Dx Illumina MiSeq

 

ISO Certification

ISO CertificationMultiplicom has obtained recognized Quality Management System certification ISO 13485:2003 & EN ISO 13485:2012 for the design, development, manufacture and distribution of in-vitro molecular diagnostic products used for identification of genomic and somatic variants. ISO 13485 is a harmonized international standard that specifies the requirements for the company's quality management system. Certification bodies use this standard to assess the company's ability to meet customer and regulatory requirements. The ISO 13485 certification establishes Multiplicom as a reliable supplier of diagnostic kits to clinical labs, as well as, to the major diagnostic companies worldwide. 

close


Management Team

Dirk Pollet

Dirk Pollet


Chief Executive Officer

Dirk Pollet

Prior to joining Multiplicom upon successful conclusion of its Series A financing on April 15th 2011, Dirk Pollet was Chief Business Officer at Cellectis since November 2008 as executive consultant for Dircs bvba. Before starting his own consultancy business Dircs bvba, he was Senior Vice President Licensing & IP at Galapagos NV in Belgium and member of the Executive Team. Prior to joining Galapagos NV in 2000, Dr. Pollet was Director Molecular Diagnostics at Glaxo Welcome in Stevenage UK. Before that he started and built the diagnostics group at Innogenetics NV where he stayed for fourteen years. Dirk Pollet holds a PhD in Biochemistry from the University of Antwerp.

Jurgen Del Favero

Jurgen Del Favero


Chief Technology Officer

Prof. Dr. Jurgen Del Favero

Prof. Dr. Jurgen Del Favero is the scientific founder of Multiplicom and acting Chief Technology Officer since the founding of the company. He is also professor at the University of Antwerp where he is leading the VIB Applied Molecular Genomics unit. Next to his scientific research in the field of psychiatric genetics, his work focuses on the development and implementation of novel nucleic acid based technologies and bioinformatics tools. He is the inventor of the technology that gave rise to Multiplicom.

Luc Segers

Luc Segers


Vice-President Marketing & Sales

Luc Segers

Luc Segers has over 25 years of experience in the clinical diagnostics industry in international commercialization, business development and strategic planning. Previously he was Senior Director Business Development at MDxHealth (formerly OncoMethylome Sciences) active in the oncology field. Prior to MDxHealth, he served as global Director Sales & Marketing at Innogenetics’ diagnostics division, and before that in several marketing positions at Organon Teknika. Mr. Segers holds a masters degree in Industrial Biochemistry.

Vicky Gwosdz

Vicky Gwosdz


Chief Financial Officer

Vicky Gwosdz

Vicky Gwosdz was Finance Manager at GTSC (J&J) between 2009 and 2011. Between 2006 and 2009 she was active as freelance author of multiple finance books and taught finance techniques at VU Amsterdam. As Head of Finance at Galapagos between 2004 and 2006, she played an important role in the company’s IPO.

Paul Vauterin

Paul Vauterin


Vice-President Informatics

Dr. Paul Vauterin

Dr. Paul Vauterin coordinates the software development activities at Multiplicom. Prior to joining Multiplicom, he worked at the University of Oxford where he was the chief architect of a suite of web-based innovative analysis and visualization tools for large-scale population genetics data. Before that, he co-founded the company Applied Maths and developed the BioNumerics software platform, which has become a global standard for the analysis of bacterial molecular typing data. Paul Vauterin holds a PhD in theoretical physics from the University of Ghent.

Ina Vandenbroucke


Vice-President Operations

Dr. Ina Vandenbroucke 

Prior to joining Multiplicom, Ina Vandenbroucke worked at Biocartis, where she gained extensive experience in IVD development in the field of oncology and infectious diseases. She held various R&D management positions and headed the Assay Design and Development team. Before joining Biocartis in 2010, Ina worked at Tibotec-Virco, Janssen Diagnostics for 7 years, where she was responsible for development of diagnostic assays in the field of virology. She implemented Next Generation Sequencing in the company, and successfully developed several NGS assays with her team. Ina holds a PhD in Medical Sciences from Ghent University.

Board of Directors

Dirk Pollet

Dirk Pollet


Chief Executive Officer

Dirk Pollet

Prior to joining Multiplicom upon successful conclusion of its Series A financing on April 15th 2011, Dirk Pollet was Chief Business Officer at Cellectis since November 2008 as executive consultant for Dircs bvba. Before starting his own consultancy business Dircs bvba, he was Senior Vice President Licensing & IP at Galapagos NV in Belgium and member of the Executive Team. Prior to joining Galapagos NV in 2000, Dr. Pollet was Director Molecular Diagnostics at Glaxo Welcome in Stevenage UK. Before that he started and built the diagnostics group at Innogenetics NV where he stayed for fourteen years. Dirk Pollet holds a PhD in Biochemistry from the University of Antwerp.

Ian Gilham

Ian Gilham


Chairman

Ian Gilham

Ian joined the Board of Axis-Shield in November 2001 from GlaxoSmithKline (GSK), where he held the position of Vice President – Pharmacogenetics. At GSK, he was responsible for the delivery of pharmacogenetic tests, as well as novel diagnostic tests used in targeting GSK's medicines. Prior to joining GSK, Ian held international general management, marketing, business development and R&D positions with Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the fields of pharmaceuticals and clinical diagnostics. In January 2007 Ian was appointed Chief Operating Officer and was promoted to Chief Executive Officer of Axis-Shield in January 2008. Whilst at Axis-Shield Ian Drove revenues to more than £100M with exceptional profit growth and cash generation. Ian led the sale of the company to Alere in 2011 for cash at a premium of 40% to the previous share price, delivering exceptional return for shareholders under tough market conditions. Ian left Axis-Shield in November 2011 once the sale to Alere was completed. Ian was appointed non-executive Chairman of Biosurfit SA in March 2013.

Rudi Marïen

Rudi Marïen


Non-Executive Director

Rudi Mariën

Rudi Mariën obtained a Master in Pharmaceutical Science at the University of Ghent  and specialized in clinical biology. He was founder, shareholder and CEO of several medical laboratories, including Barc NV, a trendsetting international central clinical laboratory, specialized in pharmaceutical studies. Mr. Mariën was vice-president of Cerba European Lab as well as cofounder, main shareholder and president of Innogenetics. He is also manager of Gengest Bvba and Biovest CommVa. Through his management company, Gengest Bvba, Mr. Mariën has mandates in the Board of Directors of both listed and unlisted companies active in biotechnology. 

Christophe Van Vaeck

Christophe Van Vaeck


Non-Executive Director

Christophe Van Vaeck

Christophe Van Vaeck (°1973) earned his PhD in Biology at the lab of Molecular and Cellular Biology at the K.U.Leuven (Belgium) in 2000. He then switched to the financial world and worked as a financial analyst Life Sciences at KBC Securities, where he guided the Euronext IPOs of Galapagos, deVGen, Thrombogenics and Ablynx. In 2008, he joined Gimv as senior investment manager. Christophe is a board observer at Multiplicom and is actively involved in the portfolio management of Ceres, Vitromics, Jenavalve and Endosense and the Gimv-Agri+ Investment Fund.

Els Beirnaert

Els Beirnaert


Non-Executive Director

Els Beirnaert

Els Beirnaert is Senior Manager, New Ventures at VIB, responsible for the establishment of start-up companies in life sciences. In this role she is engaged in business analysis and market research, identifying product opportunities, attracting venture capital funding,  corporate structuring and negotiations. Previously she was one of the start-up pioneers of Ablynx, a company established in 2001 focused on the discovery and development of biological therapeutics. As an Associate Director she was responsible for the development of Nanobodies (against TNFa, RANKL, IL6R), leading multidisciplinary project teams and translating several drug development projects from discovery to pre-clinical development to clinical development (phase 1 and phase 2a). Dr. Beirnaert obtained a Master in Biotechnology at the University of Ghent and a PhD in Biochemistry at the University of Antwerp.

Alexandra Tolia

Alexandra Tolia


Non-Executive Director

Alexandra Tolia

Alexandra Tolia is Senior Investment Manager at PMV, where she directs investments in innovative Life Sciences ventures. Since 2011 she has served as board member in several biotech companies, including FEops, iTeos Therapeutics, Apitope, Multiplicom, and the Capricorn Health-Tech Fund. Prior to PMV she led the investment strategy at Hunza Ventures, where she was instrumental in establishing the fund’s biotech portfolio in Europe and the US. For over a decade before joining the investment industry, Alexandra built an international scientific career, pioneering drug development initiatives in neurodegeneration and cardiovascular diseases, and managing key alliances between academia and the pharmaceutical industry. Alexandra holds a PhD in Medical Sciences from the University of Leuven, a degree in Management from the Solvay Brussels School of Economics and Management and is the author of several high-impact scientific publications.

Career Opportunities